MM06

Australasian Leukaemia and Lymphoma Group (ALLG)

Andrew Spencer (Alfred Hospital)

Dataset includes

• Data for 269 patients with newly diagnosed multiple myeloma using low-dose thalidomide, prednisolone and zoledronic acid versus prednisolone and zoledronic acid in a randomised trial
• Demographic data
• Diagnostic, data
• Treatment data
• Outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Cancer therapy (excl. chemotherapy and radiation therapy)

• Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study
• Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
• Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma
• Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial
• Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis
• Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au